JAK Inhibitors in 2019 Role in the therapeutic strategy in 2019 • RA: 2nd line after failure of conventional DMARDs • PsoArth: after failure of NSAID, cDMARDs and/or biologics • Ulcerative colitis: 3rd line after failure of 5-ASA, GCs, cDMARDS and anti-TNF-apha Efficacy (Rheumatoid Arthritis, Psoriatic Arthritis) • Superior to methotrexate • Noninferior to combination of methotrexate + anti-TNFapha • Efficacy as early as 3 weeks • Maximum efficacy at 3 mo. By Romain Muller via Dr. Benjamin Terrier @TerrierBen #JAKInhibitors #Indications #Rheumatology #Management
